One To Watch

DualityBio

Company Overview

A Shanghai-based clinical-stage biotech building a next-generation antibody-drug conjugate pipeline across four proprietary platforms, with a BLA accepted in China and a BioNTech partnership worth over $1.5 billion in potential milestones. DualityBio positions itself around what it calls "Super ADCs" — constructs that go beyond conventional single-target conjugates to include bispecific ADCs, novel-payload ADCs, and autoimmune ADCs. The company is running global clinical trials across 17 countries with over 3,200 patients enrolled, an operational footprint that distinguishes it from most China-originated ADC developers that confine early trials to domestic sites.

Headquarters and Global Presence

DualityBio is headquartered in Shanghai, China, and listed on the Hong Kong Stock Exchange following its April 2025 IPO. Its clinical trial network spans 17 countries, supporting a genuinely global development strategy rather than a China-first model with selective ex-China licensing.

Founding and History

DualityBio was founded by Dr. John Zhu, who continues to serve as CEO. The company progressed from private clinical-stage biotech to Hong Kong-listed entity in April 2025, raising up to HK$1.56 billion (approximately $200 million) with BioNTech committing $65 million as a cornerstone investor. That listing followed an earlier abortive attempt — DualityBio opted not to proceed with a Hong Kong IPO in February 2025 before completing it two months later. The BioNTech deal for DB-1303, signed earlier, was the commercial anchor that validated the company's platform ambitions publicly.

Therapy Areas and Focus

Oncology is DualityBio's dominant focus, with programs targeting HER2-positive breast cancer, B7-H3-expressing solid tumors, and EGFR/HER3-driven malignancies — all areas where conventional chemotherapy and first-generation HER2 agents leave meaningful residual disease burden. The company is also extending its ADC logic into autoimmune disease, a less crowded application of the modality that could widen its addressable market considerably. The commercial case for HER2-positive metastatic breast cancer alone is substantial, with trastuzumab deruxtecan setting a high clinical bar that DualityBio is explicitly trying to match or surpass.

Technology Platforms and Modalities

DualityBio's four proprietary platforms are DITAC, DIBAC, DIMAC, and DUPAC, each designed to address specific limitations of first-generation ADC architecture — linker stability, drug-antibody ratio control, payload potency, and dual-target engagement. The bispecific ADC capability (DIBAC) is commercially the most differentiated: by arming a single construct to engage two tumor antigens simultaneously, DualityBio aims to improve tumor selectivity and reduce off-target toxicity relative to monospecific predecessors. DUPAC targets autoimmune indications, recognizing that B-cell and plasma-cell depletion via ADC offers a precision alternative to broad immunosuppression.

Key Pipeline and Programs

Trastuzumab pamirtecan (DB-1303/BNT323) is the lead asset — a HER2-directed ADC that met its Phase III primary endpoint of progression-free survival in HER2-positive metastatic breast cancer in 2025. China's NMPA accepted the Biologics License Application on April 9, 2026, for the unresectable or metastatic HER2-positive breast cancer indication. BioNTech holds ex-Greater China commercial rights; DualityBio retains Mainland China, Hong Kong, and Macau.

DB-1419 is DualityBio's next-generation bispecific ADC, having received FDA IND approval and completed first global patient dosing. The asset was out-licensed to Avenzo Therapeutics' sister program: separately, AVZO-1418/DB-1418 — an EGFR/HER3 bispecific ADC — was licensed exclusively to Avenzo for development and commercialization outside Greater China in a deal carrying $50 million upfront and up to approximately $1.15 billion in milestones.

BNT324/DB-1311 is a B7-H3-targeting ADC for solid tumors, partnered with BioNTech. First data from a global Phase I/IIa trial were reported in December 2024. B7-H3 is broadly expressed across multiple solid tumor types, making this a potentially wide-indication asset if early signals hold through dose optimization.

Recent Developments

The NMPA's acceptance of the DB-1303/BNT323 BLA on April 9, 2026 is the company's most immediate regulatory catalyst, placing a potential first approval within sight. In March 2026, first post-listing financial results showed RMB3.325 billion in cash and bank balances, with positive operating cash flow recorded for the third consecutive year — an unusual financial profile for a clinical-stage biotech. DB-1419 received FDA IND clearance and dosed its first global patient, opening a U.S. clinical track. The Avenzo licensing deal for DB-1418 ($50 million upfront, up to ~$1.15 billion in milestones) was announced in January 2025.

Key Personnel

Dr. John Zhu serves as Founder and CEO, having built DualityBio from inception through its Hong Kong listing and into the BLA filing stage. Hua Mu serves as Global Chief Medical Officer, appointed in April 2025 ahead of the company's accelerated international clinical expansion; Mu's appointment was timed to coincide with the IPO and the ramp-up of multi-country Phase III operations.

Strategic Partnerships

The BioNTech collaboration is DualityBio's defining commercial relationship — $170 million upfront plus over $1.5 billion in potential milestones for DB-1303, with BioNTech also investing $65 million as IPO cornerstone. The Avenzo Therapeutics deal for DB-1418 adds $50 million upfront and up to ~$1.15 billion in milestones for the EGFR/HER3 bispecific ADC outside Greater China. BeiGene holds an exclusive option for a global clinical and commercial license to a pre-clinical ADC targeting select solid tumors, secured in a June 2024 agreement.

FAQ Section

DualityBio retains Mainland China, Hong Kong, and Macau rights across its pipeline while systematically out-licensing ex-Greater China rights to Western partners — BioNTech for DB-1303/BNT323, Avenzo for DB-1418, and BeiGene for an undisclosed pre-clinical asset. This split model generates substantial upfront cash and milestone streams while preserving the most valuable near-term commercial territory, where a China NMPA approval for DB-1303 is now within reach following BLA acceptance in April 2026.

B7-H3 is a transmembrane glycoprotein overexpressed across a wide range of solid tumor types — lung, breast, colorectal, prostate — while showing relatively low normal-tissue expression, making it a theoretically favorable ADC target for broad solid-tumor indications. First Phase I/IIa data for BNT324/DB-1311 were presented in December 2024, though at an early stage where dose-finding and tolerability remain the primary readouts. The commercially interesting question is whether B7-H3 expression breadth translates into a multi-indication approval pathway, which would substantially expand the asset's addressable population relative to a single-tumor-type label.

First-generation ADCs like trastuzumab emtansine used conventional linker-payload chemistry with limited control over drug-antibody ratio, resulting in heterogeneous conjugates with suboptimal therapeutic windows. DualityBio's four platforms — DITAC, DIBAC, DIMAC, and DUPAC — address linker stability, payload class diversity, conjugation precision, and dual-antigen targeting in combination. The bispecific capability (DIBAC) is the most structurally novel: engaging two tumor-associated antigens simultaneously is intended to improve selectivity over monospecific ADCs and potentially overcome resistance mechanisms that arise from single-antigen downregulation.

DB-1303/BNT323 met its Phase III primary endpoint of progression-free survival in HER2-positive metastatic breast cancer in 2025, and China's NMPA accepted its BLA on April 9, 2026. It competes directly with AstraZeneca/Daiichi Sankyo's trastuzumab deruxtecan, the current standard-of-care HER2-directed ADC, which means differentiation on safety profile or activity in trastuzumab deruxtecan-pretreated patients will be central to its commercial positioning. BioNTech's $170 million upfront commitment signals meaningful conviction in the asset's ex-China prospects.

Beyond HER2-positive breast cancer, DualityBio's pipeline spans B7-H3-expressing solid tumors (DB-1311, multiple tumor types), EGFR/HER3-driven cancers (DB-1418, licensed to Avenzo), and the next-generation bispecific DB-1419, which recently dosed its first patient globally after FDA IND clearance. The DUPAC platform also targets autoimmune disease, a deliberate extension of ADC logic into non-oncology indications. With over 3,200 patients enrolled across 17 countries, the trial infrastructure is already sized for a multi-indication developer rather than a single-asset company.

DualityBio is at the pivot from late-stage clinical to commercial: a Phase III win for DB-1303 in 2025, a China BLA accepted in April 2026, and DB-1419 entering Phase I globally. The company reported RMB3.325 billion in cash at its March 2026 results with positive operating cash flow for three consecutive years, suggesting a runway sufficient to absorb a commercial launch in China without immediate dilution. The NMPA review outcome for DB-1303 and full Phase III data disclosure are the two near-term events that will most sharply define the investment thesis.

The near- and medium-term watchpoints break down as follows:

NMPA decision on the DB-1303/BNT323 BLA: a first China approval would be both a revenue inflection and a platform validation signal.
Full Phase III data package for DB-1303: the primary PFS endpoint was met, but depth of response and overall survival trends will determine competitive positioning against trastuzumab deruxtecan.
DB-1419 Phase I dose-escalation data: first read from the bispecific ADC program, where the company's technical differentiation claim is most explicit.
BeiGene option exercise: whether BeiGene converts its pre-clinical option to a full license is a low-profile but meaningful signal of third-party conviction in the platform.
ADC field crowding: the HER2 ADC space is intensely competitive; any safety signal or inferior efficacy versus trastuzumab deruxtecan in pre-treated patients would materially pressure the ex-China commercial case.

Want to Update your Company's Profile?